| Authors: |
Peters D; BioNTech SE (Formerly TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH), Mainz, Germany., Kranz LM; BioNTech SE, Mainz, Germany., Eisel D; BioNTech SE, Mainz, Germany., Diken M; BioNTech SE, Mainz, Germany.; TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany., Kreiter S; BioNTech SE, Mainz, Germany.; TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University gGmbH, Mainz, Germany., Türeci Ö; BioNTech SE, Mainz, Germany.; HI-TRON-Helmholtz Institute for Translational Oncology Mainz by DKFZ, Mainz, Germany., Sahin U; BioNTech SE, Mainz, Germany.; Department of Translational Oncology and Immunology at the Institute of Immunology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany., Vormehr M; BioNTech SE, Mainz, Germany.; Department of Translational Oncology and Immunology at the Institute of Immunology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany. |
